Evidence map›Paper›PMID 31382702›Full record

ReviewMedicina (Kaunas, Lithuania)2019

"

Giuseppe Palmiero, Enrico Melillo, Antonino Salvatore Rubino

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials.European heart journal supplements : journal of the European Society of Cardiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Giuseppe PalmieroDepartment of Cardiology, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Naples, Italy. g.palmiero@hotmail.it.ORCID 0000-0002-5102-7460
Enrico MelilloDepartment of Cardiology, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Naples, Italy.ORCID 0000-0003-3829-0130
Antonino Salvatore RubinoDepartment of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.ORCID 0000-0002-9399-7422
Ospedale Monaldi · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation.

Indexed as

AnticoagulantsAtrial FibrillationFactor Xa InhibitorsHeart Valve DiseasesHumansRisk FactorsAnticoagulantsFactor Xa Inhibitorsatrial fibrillationnovel oral anticoagulantsprosthetic valve replacement

Identifiers

PMID31382702
PMCPMC6722984
OpenAlexW2966733000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.